Breast Tomosynthesis

The early detection of breast cancer using screening mammography significantly reduces mortality. However, conventional mammography still has a significant rate of both false negatives and false positives, particularly in younger women. Dexela is developing innovative technology for 3D breast imaging, which promises to significantly reduce both false negatives and false positives, allowing the earlier detection of cancer while reducing the occurrence of callbacks. Dexela has developed the leading intellectual property position covering powerful methods to acquire, process and visualize data from 3D X-ray breast imaging. Dexela is playing a central role in this field through collaborative agreements with medical device manufacturers.

Download the award winning paper Medical Physics paper to learn more about the technology.

Dexela has developed unique methods for optimised tomosynthesis acquisition, reconstruction and visualization. Dexela's tomosynthesis technology offers clinical benefits when compared with naive tomosynthesis approaches. Dexela's optimised tomosynthesis acquisition methods include variable spacing of projections, variable angular velocity and variable energy and radiation dose. Dexela's advanced tomosynthesis reconstruction software employs an iterative, statistical approach to minimise artefacts and maximise contrast.

Dexela offers a range of technologies and services to assist OEMs in the implementation of tomosynthesis capable acquisition systems and workstations, including IP licencing, consultancy and custom software development.


Page Options
printer friendly version
email to a friend



   © Dexela Limited 2010 VAT Number 872959760    Registered Company 04797594